ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 2 of 46
УЖМБС 2022, 7(1): 14–31
Medicine. Reviews

Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus

Gorb Yu. G., Serik S. A., Tkachenko O. V., Ryabukha V. V.

The issues of epidemiology, pathophysiology and basic principles of treatment of chronic heart failure in patients with type 2 diabetes mellitus are considered. Attention is paid to both means of glycemic correction and treatment of chronic heart failure directly, taking into account the effectiveness, cardiovascular safety of drugs, as well as their impact on the course and prognosis of chronic heart failure. The results of randomized clinical trials to study the effectiveness of various groups of drugs for the treatment of chronic heart failure in patients with type 2 diabetes mellitus are presented. It is indicated that the overall goal of the treatment of type 2 diabetes mellitus is to achieve and maintain glycemic control, as well as to reduce the risk of long-term complications, in particular chronic heart failure. The goal of chronic heart failure treatment is to improve the clinical condition and quality of life of patients, to reduce the frequency of hospitalizations and mortality. The appointment of some groups of hypoglycemic drugs has a neutral or negative effect on the course and prognosis of chronic heart failure, so their use is limited or not recommended in the treatment of patients with type 2 diabetes mellitus and chronic heart failure. The emphasis is on those classes of drugs that have demonstrated significant advantages in influencing the morbidity and mortality associated with chronic heart failure and type 2 diabetes mellitus in comparison with other drugs, namely, inhibitors of the sodium-dependent glucose cotransporter type 2 and angiotensin receptor inhibitors II and neprilisin (sacubitril / valsartan). Experts call such classes of drugs as sodium-dependent glucose cotransporter type 2, angiotensin receptor inhibitors II and neprilisin, mineralocorticoid receptor antagonists and beta-blockers as the "Fantastic Four", given the significant positive effect of their combined use on the course and prognosis of chronic heart failure. Modern approaches to the treatment of chronic heart failure in patients with type 2 diabetes mellitus are based on the updated guidelines of the European Society of Cardiology for the diagnosis and treatment of acute and chronic heart failure, as well as on the recommendations of the American Diabetes Association for the classification, prevention and treatment of heart failure in patients with diabetes. Conclusion. The most important achievements in recent years, which have significantly improved the treatment outcomes of patients with chronic heart failure and type 2 diabetes mellitus, include: the development of new classes of drugs; conducting large-scale randomized clinical trials that demonstrated the benefits of certain groups of drugs in terms of their impact on the development, course and prognosis of chronic heart failure in type 2 diabetes mellitus, and updated comprehensive and balanced therapy for these patients

Keywords: type 2 diabetes mellitus, chronic heart failure, treatment

Full text: PDF (Ukr) 357K

  1. Rajbhandari J, Fernandez CJ, Agarwal M, Yeap BXY, Pappachan JM. Diabetic heart disease: A clinical update. World J Diabetes. 2021;12(4):383-406. PMID: 33889286. PMCID: PMC8040078.
  2. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. 2019. Available from:
  3. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2):255-323. PMID: 31497854.
  4. American Diabetes Association. Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(1):4-6. PMID: 33298411. doi: 10.2337/dc21-Srev
  5. American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(1):34-39. PMID: 33298414.
  6. Bruemmer D, Nissen SE. Prevention and management of disease in patients with diabetes: current challenges and opportunities. Endocrinol Metab. 2020;9:81-89. PMID: 32803139. PMCID: PMC7410032.
  7. Bloomgarden Z.T. Diabetes and COVID-19. J Diabetes. 2020;12(4):347-348 PMID: 32162476.
  8. Dandona P, Ghanim H. Diabetes, Obesity, COVID-19, Insulin, and Antidiabetes Drugs. Diabetes Care. 2021 Jul 8;dci210003. PMID: 34244331.
  9. Ran J, Zhao S, Han L, Ge Y, Chong MKC, Cao W, et al. Increase Diabetes Mortality Associated With COVID-19 Pandemic in the U.S. Diabetes Care. 2021 June 29;44(7):146-147. PMID: 34135014.
  10. Spanakis EK, Yoo A, Ajayi ON, Siddiqui T, Khan MM, Seliger SL, et al. Excess Mortality in COVID-19-Positive Versus COVID-19-In patients With Diabetes: A Nationwide Study. Diabetes Care. 2021 July 7; 44(6):dc202350. PMID: 34233926.
  11. Liatis S. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care. 2021;44(6):641-646. PMID: 34155034.
  12. Beggs SA, Jhund PS, McMurray JV. Anticoagulation, atherothrombosis, heart failure: lessons from COMMANDER-HF and CORONA. Eur Heart J. 2021 May 21:42(20):5-7. PMID: 30357375.
  13. Główczyńska R, Piotrowicz E, Szalewska D, Piotrowicz R, Kowalik I, Pencina MJ, et al. Effects of hybrid comprehensive telerehabilitation cardiopulmonary capacity in heart failure patients depending on mellitus: subanalysis of the TELEREH-HF randomized clinical trial. Cardiovasc Diabetol. 2021 May 13;20(1):106. PMID: 33985509. PMCID: PMC8120915.
  14. Editorial mini team Diabetes and Metabolic Disease. Eur Heart J. 2021 Jun 14;42(23):2230. PMID: 34125888.
  15. Njoroge JN, Teerlink JR. Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circ Res. 2021 May 14;128(10):1468-1486. PMID: 33983837. PMCID: PMC8126502.
  16. Nielsen EE, Feinberg JB, Bu FL, Olsen MH, Raymond I, Steensgaard-Hansen F, et al. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. BMJ Open Heart. 2020;7(2):e001294. PMID: 33257469. PMCID: PMC7705560.
  17. Wamil M, Coleman RL, Adler AI, McMurray JJV, Holman RR. Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. Diabetes Care. 2021 Aug;44(8):1877-1884. PMID: 34162666.
  18. Tayanloo-Beik A, Roudsari PP, Rezaei-Tavirani M, Biglar M, Tabatabaei-Malazy O, Arjmand B, et al. Diabetes and Heart Failure: Multi-Omics Approaches. Front Physiol. 2021 Aug 06;12:1-12. PMID: 34421642. PMCID: PMC8378451.
  19. Rossing P. Successful glucose lowering therapy triumphs in heart failure. EClinicalMedicine. 2021 Jun 26;37:100996. PMID: 34235416. PMCID: PMC8250160.
  20. Rekomendatsiyi Vseukrayinsʹkoyi asotsiatsiyi kardiolohiv Ukrayiny ta Vseukrayinsʹkoyi Asotsiatsiyi akhivtsiv iz sertsevoyi nedostatnosti. Sertseva nedostatnistʹ u khvorykh na tsukrovyy diabet [Recommendations of the All-Ukrainian Association of Cardiologists of Ukraine and the All-Ukrainian Association of Heart Failure Specialists. Heart failure in patients with diabetes]. Ukr J Cardiol. 2020;27(3):1-36. [Ukrainian]
  21. Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, et al. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2020 Jun 7;41(22):2109-2117. PMID: 32498081. PMCID: PMC7314099.
  22. Mordi IR, Lumbers RT, Palmer CNA, Pearson ER, Sattar N, Holmes MV, et al, on behalf of the HERMES Consortium. Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study. Diabetes Care. 2021 Jul; 44(7):1699-1705. PMID: 34088700. PMCID: PMC8323186.
  23. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019; 42(3):416-426. PMID: 30104301. PMCID: PMC6385699.
  24. Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021 Feb 7;42(6):681-683. PMID: 33447845. PMCID: PMC7878007.
  25. Lin SN, Phang KK, Toh SH, Chee KH, Huri HZ. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction. Front Endocrinol (Lausanne). 2020 Jul 10;11:448. PMID: 32754118. PMCID: PMC7366349.
  26. Panʹkiv VI. Tsukrovyy diabet 2-ho typu: suchasni mizhnarodni nastanovy, personifikovanyy pidkhid i realʹna ambulatorna praktyka [Type 2 diabetes: modern international guidelines, personalized approach and real outpatient practice]. IEJ. 2020;16(6):33-40. [Ukrainian].
  27. Zhang JM, Yu RQ, Wu FZ, Qiao L, Wu XR, Fu YJ, et al. BMP 2 alleviates heart failure with type 2 diabetes mellitus and doxorubicin induced AC16 cell injury by inhibiting NLRP3 inflammasome mediated pyroptosis. Exp Therapeut Med. 2021 Aug;22(2):897. PMID: 34257710. PMCID: PMC8243329.
  28. Mann DL, Felker GM. Mechanisms and Models in Heart Failure A Translational Approach. Circ Res. 2021 May 14;128(10):1435-1450. PMID: 33983832.
  29. Itzhak B, Home P. Heart failure management; a perspective from diabetes care. Diabetes Res Clin Pract. 2021 Jun;176:108849. PMID: 33957144.
  30. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Gal TB, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021 Jun;23(6):872-881. PMID: 33932268.
  31. Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab. 2020 Dec 25;11:2042018820970444. PMID: 33489085. PMCID: PMC7768573.
  32. Bistola V, Simitsis P, Parissis J, Ouwerkerk W, van Veldhuisen DJ, et al. Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. Eur J Heart Fail. 2021 Jul;23(7):1170-1181. PMID: 33998113.
  33. Park JJ. Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes Metab J. 2021;45(2):146-157. PMID: 33813813. PMCID: PMC8024162.
  34. Chandramouli C, Teng TK, Tay WT, Yap J, MacDonald MR, Tromp J, ASIAN-HF Investigators, et al. Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. Eur J Heart Fail. 2019 Mar;21(3):297-307. PMID: 30548089.
  35. Mahmood SS, Levy D, Vasan RS, Wang TJ . The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2014 Mar 15;383(9921):999-1008.
  36. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148-158. PMID: 33031522. PMCID: PMC7542529.
  37. Voronkov LG, Tkach NA, Filatova OL, Gavrilenko TI, Dudnik GY, Lipkan NG, et al. Kliniko-instrumentalʹna kharakterystyka y p'yatyrichne vyzhyvannya cholovikiv i zhinok iz khronichnoyu sertsevoyu nedostatnistyu ta znyzhenoyu fraktsiyeyu vykydu livoho shlunochka zalezhno vid nayavnosti tsukrovoho diabetu 2-ho typu [Clinical and instrumental characteristics and five-year survival of men and women with chronic heart failure and reduced left ventricular ejection fraction depending on the presence of type 2 diabetes]. Ukr J Card. 2020;27(5):60-70. [Ukrainian].
  38. Tromp J, Lim SL, Tay WT, Teng TK, Chandramouli C, Ouwerkerk W, ASIAN-HF Investigators, et al. Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. Diabetes Care. 2019 Sep;42(9):1792-1799. PMID: 31292141.
  39. Giugliano D, Maiorino MI, Bellastella G, Esposito K. The residual cardiorenal risk in type 2 diabetes. Cardiovasc Diabetol. 2021 Feb 5;20(1):36. PMID: 33546683. PMCID: PMC7866734.
  40. Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, et al. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation. 2021 Jul 6;144(1):74-84. PMID: 34228476.
  41. Gallego M, Zayas-Arrabal J, Alquiza A, Apellaniz B, Casis O. Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes. Front Pharmacol. 2021 Jul 8;12:687256. PMID: 34305599. PMCID: PMC8295895.
  42. Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and heart failure: determinants of risk and outcomes in patients with diabetes. Prog Cardiovasc Dis. 2019;62:306-314. PMID: 31301314.
  43. American Diabetes Association. 9.Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021. Jan;44(1):111-124. PMID: 33298420.
  44. Liuzzo G, Galiuto L. GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk. Eur Heart J. 2021 May 1;42(17):1652-1653. PMID: 33822032.
  45. Shaw JA, Cooper ME. Contemporary Management of Heart Failure in Patients With Diabetes. Diabetes Care. 2020 Dec;43(12):2895-2903. PMID: 33218978.
  46. Rooney MR, Tang O, Echouffo Tcheugui JB, Lutsey PL, Grams ME, Windham BG, et al. American Diabetes Association Framework for Glycemic Control in Older Adults: Implications for Risk of Hospitalization and Mortality. Diabetes Care. 2021 Jul;44(7):1524-1531. PMID: 34006566.
  47. Zweck E, Scheiber D, Jelenik T, Bönner F, Horn P, Pesta D, et al. Exposure to Type 2 Diabetes Provokes Mitochondrial Impairment in Apparently Healthy Human Hearts. Diabetes Care. 2021 May;44(5):82-84. PMID: 33972315. PMCID: PMC8132329.
  48. Oost LJ, van der Heijden AAWA, Vermeulen EA, Bos C, Elders P JM, Slieker RC, et al. Serum Magnesium Is Inversely Associated With Heart Failure, Atrial Fibrillation, and Microvascular Complications in Type 2 Diabetes. Diabetes Care. 2021 Aug;44(8):1757-1765. PMID: 34385344.
  49. Serhiyenko OO, Serhiyenko VO. Diabetychna kardiomiopatiya: likuvannya [Diabetic cardiomyopathy: treatment]. IEJ. 2020;16(8):93-104. [Ukrainian].
  50. Choi YJ, Han KD, Choi EK, Jung JH, Lee SR, Oh S, et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. Diabetes Care. 2021 Jun;44(6):1393-1401. PMID: 33875486.
  51. Op den Kamp YJM, de Ligt M, Dautzenberg B, Kornips E, Esterline R, Hesselink MKC, et al. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care. 2021 Jun; 44(6):1334-1343.
  52. Aroor AR, Mummidi S, Lopez-Alvarenga JC, Das N, Habibi J, Jia G, et al. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness. Cardiovascular Diabetology. 2021. Apr 21;20(1):1-18. PMID: 33882908. PMCID: PMC8061206.
  53. Dębska-Kozłowska A, Książczyk M, Lelonek M. Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations rom new promising clinical trials. Heart Fail Rev. 2021 May 29. PMID: 34050489.
  54. Pérez-Belmonte LM, Ricci M, Sanz-Cánovas J, Cobos-Palacios L, López- Carmona MD , Ruiz-Moreno MI, et al. De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. EClinicalMedicine. 2021 May 8;10(9):2013. PMID: 34066707. PMCID: PMC8125841.
  55. Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovasc Diabetol. 2021 Jan 11;20(1):17. PMID: 33430860. PMCID: PMC7798345.
  56. Wang J, Lu Y, Min X, Yuan T , Wei J, Cai Z. The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study. Front Cardiovasc Med. 2021 Mar 12;8:648212. PMID: 33778026. PMCID: PMC7994337.
  57. Colling C, Atlas SJ, Wexler DJ. Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Diabetes Care. 2021 Jun;44(6):1443-1446. PMID: 34016618.
  58. Mariam A, Miller-Atkins G, Pantalone KM, Zimmerman RS, Barnard J, Kattan MW, et al. A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. Diabetes Care. 2021 Jun;44(6):1410-1418. PMID: 33863751. PMCID: PMC8247498.
  59. Kułaczkowska ZM, Wróbel M, Rokicka D, Gąsior M, Strojek K. Metformin in patients with type 2 diabetes mellitus and heart failure: a review. Endokrynologia Polska. 2021;72(2):163-170. PMID: 33970481.
  60. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 Sept 21;42(36):3599-3726. PMID: 34447992.
  61. American Diabetes Association .Addendum. 10.Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jun 16;44(1):125-50. PMID: 33298421.
  62. Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J. 2021 Jul 7;42(26):2565-2573. PMID: 33197271.
  63. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-1424. PMID: 32865377.
  64. Zannad F, Ferreira JP , Pocock SJ , Anker SD , Butler J , Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829.
  65. Pellicori P, Fitchett D, Kosiborod MN, Ofstad AP, Seman L, Zinman B, et al. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2021 Jul;23(7):1085-1093. PMID: 34031968.
  66. Joshi SS, Singh T, Newby DE, Singh J. Sodium- glucose co- transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021Feb 26;107(13):1032-1038. PMID: 33637556. PMCID: PMC8223636.
  67. Neuen BL, Arnott C, Perkovic V, Figtree G, de Zeeuw D, Fulcher G, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab. 2021;23:382-390. PMID: 33043620. PMCID: PMC7821162.
  68. Cai RP, Xu YL, Su Q. Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis. Cardiol Res Pract. 2021 Mar 30;2021:6657380. PMID: 33859839. PMCID: PMC8026320.
  69. Kahkoska AR, Abrahamsen TJ, Alexander GC, Bennett TD, Chute CG, Haendel MA, et al. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. Diabetes Care. 2021 Jul;44(7):1564-1572. PMID: 34135013. PMCID: PMC8323175.
  70. Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, et al. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care. 2020;43(7):1546-1552. PMID: 32366578. PMCID: PMC7305014.
  71. Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, et al. Effects of glucagon- like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Dec;22(12):2487-2492. PMID: 32744418. PMCID: PMC7754406.
  72. He S, Qian X, Chen Y, Shen X , Zhang B, Chen X, et al. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study. J Diabetes Res. 2021 Jun 11;2021:1-10. PMID: 34222493. PMCID: PMC8213465.
  73. Sokolova LK, Belchina YuB, Pushkarev VV, Cherviakova SA, Vatseba TS, Kovzun OI, et al. Vplyv likuvannya metforminom na rivenʹ GLP-1, NTproBNP ta endotelinu-1 u krovi khvorykh na tsukrovyy diabet 2-ho typu [The effect of metformin treatment on the level of GLP-1, NTproBNP and endothelin-1 in the blood of patients with type 2 diabetes]. IEJ. 2020;16(8):26-31. [Ukrainian]. 0721.16.8.2020.222882
  74. Matthews DR, Paldonius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208): 1519-1529. PMID: 31542292. (19)32131-2
  75. Yargin SV. Ranneye naznacheniye insulina pri sakharnom diabete 2-go tipa: plyusy i minusy [Early insulin administration for type 2 diabetes mellitus: pros and cons]. IEJ. 2021 May;17(2):169-174. [Russian].
  76. Hanefeld M, Fleischmann H , Siegmund T, Seufert J. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Ther. 2020 Aug;11(8):1645-1666. PMID: 32564335. PMCID: PMC7376805.
  77. Bhatt AS, Varshney AS, Nekoui M, Moscone A, Cunningham JW, Jering KS, et al. Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. Eur J Heart Fail. 2021 Jul;23(7):1191-1201. PMID: 33768599.
  78. Masarone D, Martucci ML, Errigo V, Pacileo G. The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction. J Cardiovasc Dev Dis. 2021;8(9):101. PMID: 34564119. PMCID: PMC8468030.
  79. Schwartz B, Pierce C, Madelaire C, Schou M, Kristensen SL, Gislason GH et al. Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. J AНА. 2021 Sep 17;10(18):e021310. PMID: 34533058. PMCID: PMC8649547.
  80. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):507. PMID: 33029625.
  81. Gopinathannair R, Chen LY, Chung MK, Cornwell WK, Furie KL, Lakkireddy DR, et al. Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol. 2021 Jun 15;14(7):e000078.
  82. Chourdakis E, Koniari I, Velissaris D, Tsigkas G, Kounis NG, Osman N. Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. J Geriatr Cardiol. 2021 May 28;18(5):362-375.
  83. Mazza A, Townsend DM, Torin G, Schiavon L, Camerotto A, Rigatellie G, et al. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings. Biomed Pharmacother. 2020 Oct;130(9):110596. PMID: 34321170.
  84. Hsieh HL, Chen CY, Chen CH, Hsu SC, Huang WC, Sue YM, et al. Renal protective effect of sacubitril/valsartan in patients with heart failure. Sci Rep. 2021;11:1-10. PMID: 33633282. PMCID: PMC7907094.
  85. Januzzi Jr JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085-1095. PMID: 31475295. PMCID: PMC6724151.
  86. Kim HM, Kim KH, Park JS, Oh BH. Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy. Medicina (Kaunas). 2021 Apr 25;57(5):416. PMID: 33922990. PMCID: PMC8146255.
  87. Gupta V, Teli V. 1069-P: Effect of Sacubitril/Valsartan Combination Therapy in Type 2 Diabetes Mellitus Patients with Elevated NT-proBNB and Preserved Ejection Fraction. Diabetes. 2020 Jun; 69(1):1069-P.
  88. Jaffuel D, Nogue E, Berdague P, Galinier M, Fournier P, Dupuis M, et al. Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study. ESC Heart Fail. 2021 Aug;8(4):2513- 2526. PMID: 34102018. PMCID: PMC8318447.
  89. Fu S, Xu Z, Lin B, Chen J, Huang Q, Xu Y, et al. Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis. Front Med (Lausanne). 2021 Jun 21;8:657067. PMID: 34235161. PMCID: PMC8255468.
  90. Cardoso R, Graffunder FP, Ternes CMP, Fernandes A, Rocha AV, Fernandes G, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021 Jun 5;36:100933. PMID: 34308311. PMCID: PMC8257984.
  91. Volpe M, Patrono C. The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. Eur Heart J. 2021 Apr 14;42(15):1458-1459. PMID: 33704413.
  92. Sattar N, McGuire DK. Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J. 2021 Jul 7;42(26):2574-2576. PMID: 33200189.
  93. Kim HMK, Hwang IC, Wonsuk Choi W, Yoon YE, Cho GY. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. Sci Rep. 2021 Nov 16;11(1):22342. PMID: 34785723. PMCID: PMC8595580.
  94. Persson F, Rossing P, Vart P, Chertow GM, Hou FF, Jongs N, et al for the DAPA-CKD Trial Committees and Investigators. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care. 2021 Aug;44(8):1894-1897. PMID: 34183431. PMCID: PMC8385469.
  95. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-128. PMID: 33200892.
  96. Januzzi JL, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, et al. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021 Sep;78(13):1321-1332. PMID: 34556318.
  97. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2020 Apr;42(13):1203- 1212. PMID: 33420498. PMCID: PMC8014525.
  98. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021 Mar;77(11):1381-1392. PMID: 33736819.
  99. Zannad F, Cowie MR. Circulation. VERTIS-CV More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit. Circulation. 2020;142(23):2216-2218. PMID: 33284652.
  100. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8; 383:1425-1435. PMID: 32966714.
  101. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al., for the CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380:2295-2306. PMID: 30990260.
  102. Szarek M, Bhatt DL, Steg G, Cannon CP , Leiter LA, McGuire DK , et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021 Aug;174(8):1065-1072. PMID: 34152828.
  103. Ding Nguyen. 57th EASD: Sotagliflozin for Type 2 Diabetes. Diabetes In Control. 2021 Nov 6. Available from:
  104. Avgerinos I, Karagiannis T, Kakotrichi P, Michailidis T, Liakos A, Matthews DR, et al. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2021 Sept 20;24(1):106-114. PMID: 34545668.
  105. Bertram P, Deepak LB. Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes? Circulation. 2021 Jul 6;144(1):4-6. PMID: 33887961.
  106. Ferreira JP, Eschalier R, Duarte K, Damman K, Gustafsson F, Schou M, et al. Reduced Diuretic Dose in Patients Treated With Eplerenone. Circ Heart Fail. 2020 May;13(5):e006597. PMID: 32354280.
  107. Brandt-Jacobsen NH, Madsen PL, Johansen ML, Rasmussen JJ, Forman JL, Holm MR, et al. Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes: Data From the MIRAD Trial. JACC Heart Fail. 2021 Aug;9(8):550-558. PMID: 34325885.
  108. Brandt-Jacobsen NH, Johansen ML, Rasmussen J, Forman JL, Holm MR, Faber J, et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial. Diabetes Metab. 2021 Jul;47(4):101190. PMID: 32919068.
  109. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105-14. PMID: 27130705. PMCID: PMC4946749.
  110. Liuzzo G, Volpe M. FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2021 Oct 18; ehab725. PMID: 34905601.
  111. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. The RECEDE-CHF Trial. Circulation. 2020 Nov;142(18):1713-1724. PMID: 32865004. PMCID: PMC7594536.
  112. Pohar R, MacDougall D. Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Feb 13. CADTH Rapid Response Reports. PMID: 33074620 Bookshelf ID: NBK562925
  113. Lee YH, Lin PL, Chiou WR, Huang JL, Lin WY, Liao CT, et al. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction. ESC Heart Failure. 2021 April;8(2):1204-1215. PMID: 33410280. PMCID: PMC8006660.
  114. Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure EventInsights From the VICTORIA Trial. JAMA Cardiol. 2021 Jun 1;6(6):706-712. PMID: 33185650. PMCID: PMC7666431.
  115. Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, et al. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. Results From the COSMIC-HF Study. Circ Heart Fail. 2020 Nov 12;13(12):e007814.
  116. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021 Jan14;384:105-116. PMID: 33185990.
  117. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(1):15-33. PMID: 33298413.